Novonesis A/S

NSIS B

DK0060336014

Specialty Chemicals

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:38 2024-05-31 am EDT			5-day change	1st Jan Change
408.6 ^DKK	-0.90%		-3.65%	+10.11%

May. 10	NOVONESIS : Key segments outperform in average Q1 24 showing
May. 03	Transcript : Novozymes A/S, Q1 2024 Sales/ Trading Statement Call, May 03, 2024

Trading by management and close relations of management

May 17, 2024 at 06:40 am EDT

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B in the attached file.

Investor Relations
Tobias Bjorklund	+45 3077 8682	tobb@novonesis.com
Anders Enevoldsen	+45 5350 1453	adev@novonesis.com
Disa Tuominen	+45 6038 5826	ditu@novonesis.com

Attachment

2024_17_Trading_By_Management

Latest news about Novonesis A/S

NOVONESIS : Key segments outperform in average Q1 24 showing	May. 10
Transcript : Novozymes A/S, Q1 2024 Sales/ Trading Statement Call, May 03, 2024	May. 03
Novonesis Provides Sales Guidance for the Year 2024	May. 03	CI
Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023	Apr. 30	CI
Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023	Apr. 08	CI
China to speed up 'new productive forces', vice president says	Mar. 26	RE
Nordic Shares Rose Thursday; Embracer Group Series B Topped Leaders	Mar. 21	DJ
Transcript : Novozymes A/S, 2024 Guidance/Update Call, Mar 21, 2024	Mar. 21
Novonensis expects 2024 adjusted EBITDA margin of 35%	Mar. 21	RE
Novonesis Provides Earnings Guidance for the Year 2024	Mar. 21	CI
Biotalys, Novonesis Sign Deal to Advance Biofungicide Candidate Development	Mar. 18	MT
Biotalys and Novonesis Announces Manufacturing and Commercialization Partnership for EVOCA NG	Mar. 18	CI
FMC Partners With Novonesis in Canada for Biosolution Products	Mar. 12	MT
Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West	Mar. 07	CI
Novozymes A/S Announces Board Appointments	Mar. 04	CI
Transcript : Novozymes A/S - Shareholder/Analyst Call	Mar. 04
Novo Nordisk's controlling shareholder plans to invest about $35 billion by 2030	Feb. 12	RE
Novozymes A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
NOVOZYMES : Q4 23: destocking noise offsets recovery in other key segments	Feb. 08
Novozymes, Chr. Hansen Complete Merger Settlement	Feb. 02	MT
Transcript : Novozymes A/S, 2023 Earnings Call, Feb 01, 2024	Feb. 01
Novozymes Completes Merger with Chr. Hansen After Securing Final Registration, Issuing B Shares	Jan. 29	MT
Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S.	Jan. 28	CI
Novozymes, Chr. Hansen’s Proposed Merger Secures All Regulatory Approvals	Jan. 26	MT
Novozymes, Chr. Hansen Merger Wins Korean Regulatory Nod	Dec. 20	MT

Chart Novonesis A/S

Duration

Period

More charts

Company Profile

Novonesis A/S (formerly Novozymes A/S) is the world's leading producer of enzymes and microorganisms for industrial companies. Net sales break down by market as follows: - industry of cleaning and household maintenance products (28.5%); - bioenergy (24.8%); - food industry and human health (22.1%); - technical and cereal industries (12.8%): microorganisms used in the field of wastewater treatment, technical enzymes intended for the textile, leather, pulp and paper industries; - agriculture and animal feed industry (11.8%): enzymes used to improve the productivity and digestion of certain foods. Net sales are geographically distributed as follows: Denmark (1.3%), Europe/Middle East/Africa (33.5%), North America (33.9%), Asia/Pacific (18.5%) and Latin America (12.8%).

Sector

Specialty Chemicals

Calendar

2024-06-18 - Capital Markets Day

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVONESIS : Key segments outperform in average Q1 24 showing

May 10, 2024 at 12:32 pm EDT

More Strategies

Ratings for Novonesis A/S

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

408.6 DKK

Average target price

437.4 DKK

Spread / Average Target

+7.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Industrial Biotechnology Chemicals

	1st Jan change	Capi.
NOVONESIS A/S	+10.11%	27.6B
CATHAY BIOTECH INC.	-11.53%	3.9B
BORREGAARD ASA	+12.25%	1.83B
PUYANG HUICHENG ELECTRONIC MATERIAL CO., LTD.	-4.30%	683M
HENAN JINDAN LACTIC ACID TECHNOLOGY CO.,LTD.	-21.50%	421M
BIO-ON S.P.A.	-81.65%	216M
CHEMCON SPECIALITY CHEMICALS LIMITED	-18.97%	104M
I-TECH AB	-6.88%	58.11M

Industrial Biotechnology Chemicals

Novonesis A/S

Equities

NSIS B

DK0060336014

Specialty Chemicals

Trading by management and close relations of management

EPS Revisions